Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eliza Slawther

Senior Writer

London, UK

Eliza began reporting on health and medical science in 2018 while completing her Master’s degree in Journalism at City, University of London. During her degree program she interned at C+D and on the London Evening Standard’s health desk. In the years since, Eliza has written about everything from mid-stage drug development to market access for medicines and devices in the EU and beyond. Her work explores the trials and tribulations of securing reimbursement for medical products in Europe, and Eliza is particularly interested in the challenges of funding innovation in health care.

Eliza has lived in London since 2017 and is originally from Cheshire, in the north west of England. She has a BA in English Literature from the University of Manchester and is in the process of completing a second undergraduate degree in Biomedicine from Birkbeck College, an evening university that is part of the University of London.

Latest From Eliza Slawther

New UK Government ‘Championing’ Life Sciences, But No ‘Big Changes’ Expected For Pharma

While the new Labour government includes several “life sciences champions” and has pledged to turn the UK into a life sciences powerhouse, the UK BioIndustry Association head says major changes are unlikely for the pharma and biotech industry.

Europe United Kingdom

EFPIA: EU Must Up The Budget Of Next R&D Funding Framework

The European Commission’s new research and innovation funding scheme should have a higher budget and be more “flexible and fit-for-purpose” than the existing “one-size-fits-all approach,” pharma industry federation EFPIA says.

BioPharmaceutical Europe

Another Funding Win For Chiesi In Europe As Scotland OKs Elfabrio

Scotland’s health technology assessment body has agreed to reimburse Chiesi’s Elfabrio for Fabry disease, mirroring the decision from several other European countries – however, France turned down the rare disease drug, while Germany questioned its benefit.

BioPharmaceutical Health Technology Assessment

Why CAR T Therapies Are Hard To Scale, And How Challenges Can Be Solved

Chimeric antigen receptor T-cell (CAR-T) therapies have revolutionized the treatment of blood cancer, but scalability remains a major challenge. Experts explain how technologies such as chip-based miniaturized models and automation could be part of the solution.

Manufacturing Business Strategies

Novartis’ Gene Therapy Luxturna Gets Routine Funding In Scotland

Scotland’s health technology assessment body has granted routine reimbursement to Novartis’ vision loss drug Luxturna after an interim funding period via its ultra-orphan pathway, while Chiesi’s Filsuvez is set to begin its journey on the same pathway.

Europe United Kingdom

EU Offers Research Funding For Regulatory Sandboxes And Novel Endpoint Projects

Europe’s Innovative Health Initiative, a public-private funding partnership, has put out a call for a research project that could help analyze the use of regulatory sandboxes in health care innovation in addition to three others.

Europe BioPharmaceutical
See All
UsernamePublicRestriction

Register